Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serlopitant for Pruritus in Adults With Prurigo Nodularis
2017-004210-25Phase 3Completed
- Sponsor
- Menlo Therapeutics Inc.
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pruritus and prurigo nodularis (PN) comparing Serlopitant with Placebo (2 arms). Primary endpoint: Worst-Itch Numeric Rating Scale 4-point responder rate. Started Feb 2018; status: completed.
02
Drugs
serlopitant
03
Conditions
pruritusprurigo nodularis (PN)
Beyond the preview
Go deeper on 2017-004210-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004210-25.